Supriya Ghosh (Editor)

Omarigliptin

Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Covid-19
Routes of administration  Oral
Legal status  Developing
CAS Number  1226781-44-7
Molar mass  398.4275 g/mol
ATC code  None
Synonyms  MK-3102
PubChem CID  46209133
Omarigliptin httpswwwmedchemexpresscomproductpichy1598

Omarigliptin (MK-3102) is a potent, long-acting oral antidiabetic drug of the DPP-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by Merck & Co. It inhibits DPP-4 to increase incretin levels (GLP-1 and GIP), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying and decreases blood glucose levels.

History

Marizev (omarigliptin) 25 mg and 12.5 mg tablets were approved by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) on 28th Sept 2015. Japan was the first country to have approved omarigliptin. However Merck has announced that the company will not submit marketing application in the US and Europe.

References

Omarigliptin Wikipedia


Similar Topics
King Corn (film)
Julian Burnside
Shawn Arévalo McCollough
Topics
 
B
i
Link
H2
L